Literature DB >> 11728846

First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies.

Wolfgang Gaebel1, Michaela Jänner, Nicole Frommann, Adolf Pietzcker, Wolfgang Köpcke, Michael Linden, Peter Müller, Franz Müller-Spahn, Joachim Tegeler.   

Abstract

Results of studies on intermittent neuroleptic treatment strategies in first episode (FE) schizophrenia have not been published. Aims of the present study were to elucidate the comparative efficacy of prodrome-based neuroleptic intervention in first vs multiple episode (ME) schizophrenia. As to the methods, three randomly assigned open neuroleptic treatment strategies were compared over 2 years in 363 schizophrenic outpatients (115 FE, 248 ME; ICD-9, RDC): maintenance medication vs two intermittent medication strategies (prodrome-based intervention and crisis intervention). Concerning relapse prevention, the results demonstrate that ME patients seemed to profit most from maintenance medication compared to both intermittent treatments, whereas FE patients did equally well under maintenance medication and prodrome-based intervention treatment. Psychopathology, social adjustment, subjective well-being, and side-effects after two years did not differ significantly between the FE and ME patients irrespective of treatment strategy. Concerning treatment adherence, FE patients complied better with prodrome-based intervention than with maintenance medication. Cumulative neuroleptic dosage was lowest in FE patients under intermittent treatment. In conclusion, maintenance medication is the best strategy for relapse prevention in ME patients. In FE patients, prodrome-based intermittent intervention seems to be equivalent or even better with respect to compliance and dosage applied.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11728846     DOI: 10.1016/s0920-9964(01)00182-7

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  18 in total

Review 1.  [Pharmacotherapy for schizophrenia].

Authors:  W W Fleischhacker; W Hummer
Journal:  Nervenarzt       Date:  2006-11       Impact factor: 1.214

Review 2.  Unanswered questions in schizophrenia clinical trials.

Authors:  John M Kane; Stefan Leucht
Journal:  Schizophr Bull       Date:  2008-01-16       Impact factor: 9.306

3.  Does Non-Adherence Increase Treatment Costs in Schizophrenia?

Authors:  Mark Pennington; Paul McCrone
Journal:  Pharmacoeconomics       Date:  2018-08       Impact factor: 4.981

4.  Plasma levels and estimated dopamine D2 receptor occupancy of long-acting injectable risperidone during maintenance treatment of schizophrenia: a 3-year follow-up study.

Authors:  Saeko Ikai; Takefumi Suzuki; Masaru Mimura; Hiroyuki Uchida
Journal:  Psychopharmacology (Berl)       Date:  2016-09-08       Impact factor: 4.530

5.  Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects.

Authors:  Ryosuke Arakawa; Hiroshi Ito; Akihiro Takano; Masaki Okumura; Hidehiko Takahashi; Harumasa Takano; Yoshiro Okubo; Tetsuya Suhara
Journal:  Psychopharmacology (Berl)       Date:  2010-03-27       Impact factor: 4.530

Review 6.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

7.  Open-ended and Open-door Treatment Groups for Young People with Mental Illness.

Authors:  Rachel Miller; Susan E Mason
Journal:  Soc Work Groups       Date:  2012

Review 8.  Antipsychotic medication for early episode schizophrenia.

Authors:  John Bola; Dennis Kao; Haluk Soydan
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

Review 9.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Authors:  Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

10.  Neuropsychological impairments predict the clinical course in schizophrenia.

Authors:  Wolfgang Wölwer; Jürgen Brinkmeyer; Mathias Riesbeck; Lena Freimüller; Ansgar Klimke; Michael Wagner; Hans-Jürgen Möller; Stefan Klingberg; Wolfgang Gaebel
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.